I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma

BACKGROUND: I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (~ 185 MBq, 10 mg). Seven of these patients undergoing sorafenib/immunotherapy w...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:EJNMMI Res
Glavni autori: Carrasquillo, Jorge A., O’Donoghue, Joseph A., Beylergil, Volkan, Ruan, Shutian, Pandit-Taskar, Neeta, Larson, Steven M., Smith-Jones, Peter M., Lyashchenko, Serge K., Ohishi, Norihisa, Ohtomo, Toshihiko, Abou-Alfa, Ghassan K.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2018
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838028/
https://ncbi.nlm.nih.gov/pubmed/29508107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-018-0374-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items